Company intelligence / Profile preview

Biosignatures

Newcastle upon Tyne, England, United Kingdomastrobiology.nasa.gov ↗

Ownership: Private
Development stage: Other

Overview

Biosignatures developed a proprietary AI-driven cloud software platform capable of highly sensitive multiplexed protein biomarker analysis from blood samples. The company successfully identified a biomarker for prostate cancer, which is currently in clinical validation, and discovered additional potential biomarkers related to Alzheimer’s disease and various cancers. The company is now in liquidation; its IP assets are available for acquisition.

Therapeutic areas: OncologyNeurology
Modalities: Diagnostic software platformBiomarker analysis (protein biomarkers)
Industry: Protein Biomarker Diagnostics

Beyond the preview

Go deeper on Biosignatures.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Biosignatures.

Explore the full profile